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Cost Effectiveness Of Everolimus-Eluting Stents Compared To First
Generation Drug-Eluting Stents In Contemporary Clinical Practice
Robert Applegate1, Matthew Sacrinty1, Sanjay Gandhi1, Michael Kutcher1,
Renato Santos1, Timothy Smith1, William Little1
1Wake Forest School of Medicine, Winston-Salem, NC
Background: Everolimus-eluting stents (EES) reduce adverse clinical outcomes com-
pared to first generation drug-eluting stents (DES) and cost less. Whether EES demon-
strate cost-effectiveness compared to DES within high risk patient subgroups is uncertain.
Methods: Percutaneous coronary intervention with EES (n1,003) and 1st generation
DES (n992) were performed at a single center (Wake Forest Baptist Medical Center)
between January 2007 and December 2010. One-year target lesion revascularization
(TLR) incidence and costs in 2010 dollars were prospectively evaluated and compared
within patient subgroups. Follow-up was 94% for both groups.
Results: Overall baseline characteristics were similar, except for higher use of EES for
ST-elevation myocardial infarction. Clopidogrel use at 1 year was 88% EES vs. 91% DES
(p0.02). Overall, EES was associated with 1.1 less TLR events per 100 patients
compared to DES. Aggregate 1-year costs were $765 less ($1,293 less to $197 less) with
EES (p0.005). EES demonstrated economic dominance (lower costs and TLR inci-
dence) compared to DES in all patient subgroups (see Table).
Cost effectiveness results for patient subgroups
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5172 5937 765 1.1 Dominant 98.6% Dominant 95.5%
Males
(n1399)
4997 5942 945 2.4 Dominant 99.2% Dominant 97.7%
Females
(n596)
5625 5927 303 0.6 Dominant 60.2% Dominant 47.4%
Age 75 y
(n356)
4598 6020 1421 4.1 Dominant 99.0% Dominant 98.2%
Age 75 y
(n1639)
5288 5918 630 1.3 Dominant 91.0% Dominant 81.7%
Diabetics
(n655)
5462 6673 1211 3.6 Dominant 97.7% Dominant 94.3%
Non-
diabetics
(n1340)
5032 5574 542 0.9 Dominant 89.8% Dominant 80.1%
ST-
elevation
MI
(n419)
4776 5303 527 0.1 Dominant 45.0% Dominant 57.6%
Non-ST-
elevation
ACS
(n1197)
5221 6065 844 2.5 Dominant 98.5% Dominant 93.6%
Off-label
indications
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5388 6218 830 2.2 Dominant 98.4% Dominant 95.9%
On-label
indications
(n388)
4343 4681 338 0.3 Dominant 55.1% Dominant 49.7%
*Percentages based on 1,000 bootstrap resamplings. ACS indicates acute coronary syndrome; MI,
myocardial infarction; QALY, quality adjusted life year; TLR, target lesion revascularization.
Conclusions: In this prospective observational registry EES was economically dominant
compared to 1st generation DES in a variety of patient subgroups, including PCI for acute
coronary syndrome and off-label indications.
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Background: The RESOLUTE International (R-INT) trial has demonstrated the safety
and effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) through 2 years in a
real-world population of patients with coronary artery disease requiring percutaneous
coronary intervention (PCI). Concerns regarding long-term safety of drug-eluting stents,
particularly in complex patients and lesions, require ongoing follow-up of clinical trials to
confirm safety and effectiveness.
Methods: The R-INT observational trial prospectively enrolled 2349 patients at centers
across Europe, Argentina, India, and South Africa to undergo PCI using the R-ZES.
Minimal exclusion criteria assured a broad representation of real-world clinical practice.
The primary endpoint was a composite of cardiac death and target-vessel myocardial
infarction (CD/TV-MI). A key secondary endpoint was ARC definite and probable stent
thrombosis. Dual antiplatelet therapy with aspirin and clopidogrel was recommended for
6 months and was prescribed thereafter at operator’s discretion. Death, TV-MI, stent
thrombosis, and target vessel revascularization (TVR) events were adjudicated using the
same definitions and criteria as employed in the Global RESOLUTE Clinical Program.
Results: Two year follow-up was available for 2296 (97.7%) of patients enrolled.
Baseline characteristics include 78% males, mean age of 63.5 years, with 20% presenting
with acute MI and 26.1% with unstable angina; 30.5% of patients had diabetes mellitus.
Two-thirds of the patients were considered complex based on clinical and lesion
characteristics. At 2 years 43.9% of patients were receiving dual antiplatelet therapy. Two
year clinical outcomes include 5.9% CD/TV-MI, 4.5% death, 4.9% target lesion
revascularization, and 6.3% TVR. Very late definite and probable stent thrombosis was
0.1% for the period between 1to 2 years.
Conclusions: At 2 years after R-ZES implantation there is a very low rate of stent
thrombosis and clinical event rates are consistent with 2 year results in 1121 patients
treated with a R-ZES in the RESOLUTE All Comers trial. The final 3 year clinical
follow-up of this large, observational study will be reported.
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A Novel Bioactive and Coating-Free Stent Surface Exhibits a Reduction in
Neointimal Hyperplasia by Decreasing Platelet Aggregation and Promoting
Endothelialization
Lynn Bailey1, Adam Groothuis1, Arik Zucker2, Stefano Buzzi2, Armin Mäder2,
Algirdas Ziogas3, Vincent Milleret3, Martin Ehrbar3, Elazer Edelman4
1CBSET, Inc., Lexington, MA, 2Qvanteq AG, Zurich, Switzerland, 3University
Hospital Zurich, Zurich, Switzerland, 4Harvard-MIT Biomedical Engineering
Center, Cambridge, Massachusetts
Background: Qvanteq has applied its novel coating-free bioactive surface technology
onto bare metal stents (BMS).
Methods: In-Vivo: Integrity BMS, Qvanteq-treated Integrity stents (QBM), and Resolute
DES were randomly implanted in a swine coronary artery model up to 90d with
angiographic and histopathological assessments. In-Vitro: treated (QBM) and untreated
CoCr disks were incubated with heparinized human blood for 2 hrs and the adherent blood
components were investigated by immunofluorescence microscopy or SEM. Proliferation
assays were performed using human aortic endothelial cells for up to 96 hrs.
Results: In-Vivo: Quantitative angiography demonstrated a reduction (p0.05) of late
lumen loss and percent stenosis in QBM compared to BMS at 30d and DES at 30 and 90d.
Neointimal area was decreased (p0.05) in QBM compared to BMS and DES. Light
microscopy showed vascular injury, inflammation, and adventitial fibrosis of the QBM
was reduced (p0.05) compared to DES at 30d. Endothelialization was complete in the
QBM and BMS groups and near complete in the DES group. Analogous results were
obtained with treated Multi-Link and Omega stents compared to their untreated BMS and
DES counterparts. In-Vitro: A 10-fold decrease in platelet adhesion and a 5-fold increase
in neutrophil recruitment were observed on the QBM surface compared to the untreated
surface. Proliferative endothelial cell assays at 2d were slightly higher for QBM
(85.8%3.2 coverage) compared to untreated surfaces (78.6%11.2). At 4d cell growth
was comparable with confluent cell coverage on both surfaces (95% coverage).
Conclusions: The QBM surface significantly reduced neointimal hyperplasia in swine
coronaries compared to both BMS and DES, independently from stent design and/or
alloy, without adverse vascular healing effects. In-Vitro data indicate that those results
may be related to a significant reduction of adherent platelets combined with enhanced
neutrophil adhesion, which promote reendothelialization and decrease neointimal hyper-
plasia by locally regulating acute inflammatory response and endothelial recovery.
Therefore, this novel approach may be an effective alternative to DES in reducing clinical
in-stent restenosis.
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Late Catch-up Restenosis of Drug Eluting Stents: Evidence from Comparison
with Bare Metal Stents in Japanese CAD Patients
Yuki Horita1, Masatoshi Ikeda1, Isao Inoki2, Masanobu Namura1, Kenji Sakata1,
Hedenobu Terai3
1Kanazawa Cardiovascular Hospital, Kanazawa City, Ishikawa Prefecture,
2Kanazawa Cardiovascyular Hospital, Kanazawa City, Ishikawa Prefecture,
3Kanazawa Cardiovascular Hospital, Kanazawa city, Ishikawa Prefecture
Background: Although incidence of initial restenosis in coronary stenting lesions was
dramatically decreased by use of drug-eluting stent (DES), few data exist regarding late
catch-up restenosis of DES during long term follow-up in Japanese patients. Therefore,
we clarified the efficacy of DES for restenosis in the initial and late catch-up in
comparison with those of bare metal stent (BMS).
Methods: We analyzed 1478 lesions of BMS and 2959 of DES. DESs consisted of the
2091 sirolimus (SES; Cypher & Cypher-Select), 357 paclitaxel (PES; Taxus & Taxus-
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